Gulcan Erim, Toker Serdar, Hatipoğlu Hasan, Gulcan Aynur, Toker Aysun
Department of Internal Medicine, Orthopedics and Periodontology, Hospital of Dumlupinar University, Kutahya, Turkey.
Am J Med Sci. 2008 Nov;336(5):379-82. doi: 10.1097/MAJ.0b013e31816a05f2.
To evaluate the efficacy of cyanocobalamin treatment in patients having recurrent aphthous ulcers (RAUs) with normal or decreased serum vitamin B12 (cobalamin) levels.
Seventy-two patients with RAU were included in the study. In addition to serum cobalamin levels, hemanitic and biochemistrical parameters were measured. Patients with serum cobalamin levels < 140 pg/mL were defined as the cobalamin deficient group (CDG) whereas patients with cobalamin levels > or = 140 pg/mL were defined as the cobalamin normal group (CNG). The degree of aphthous ulcer healing was determined according to serum cobalamin levels at the first and sixth month after cyanocobalamin treatment protocol.
Of the 72 participants, 37 were in the CDG whereas 35 were considered to have normal cobalamin levels. In the first admission the cobalamin levels were 215.8 +/- 116.90 pg/mL in CNG and 107.43 +/- 29.35 pg/mL in the CDG. The frequency of aphthous ulcers was defined numerically according to monthly occurrence of the lesions. The mean aphthous ulcer frequency in CNG group was 1.9 +/- 0.7, whereas it was 2.4 +/- 0.9 in the CDG. A significant increase in cobalamin levels was observed after cyanocobalamin treatment in both groups. A significant decrease in aphthous ulcer frequency was also concurrently observed. 96% of the patients showed good response to replacement treatment, 4% of the study population did not respond to the treatment.
Cyanocobalamin treatment maybe beneficial for patients with RAU even when serum cobalamin levels are normal. We suggest that higher serum cobalamin levels should be attained in patients with RAU for mucosal protection.
评估氰钴胺治疗血清维生素B12(钴胺素)水平正常或降低的复发性阿弗他溃疡(RAU)患者的疗效。
72例RAU患者纳入本研究。除检测血清钴胺素水平外,还测定了血液学和生化指标。血清钴胺素水平<140 pg/mL的患者被定义为钴胺素缺乏组(CDG),而钴胺素水平≥140 pg/mL的患者被定义为钴胺素正常组(CNG)。根据氰钴胺治疗方案后第1个月和第6个月的血清钴胺素水平确定阿弗他溃疡的愈合程度。
72名参与者中,37人属于CDG组,35人被认为钴胺素水平正常。首次入院时,CNG组的钴胺素水平为215.8±116.90 pg/mL,CDG组为107.43±29.35 pg/mL。阿弗他溃疡的发生频率根据每月出现的病损数量进行量化定义。CNG组阿弗他溃疡平均发生频率为1.9±0.7,而CDG组为2.4±0.9。两组在氰钴胺治疗后钴胺素水平均显著升高。同时,阿弗他溃疡发生频率也显著降低。96%的患者对替代治疗反应良好,4%的研究对象对治疗无反应。
即使血清钴胺素水平正常,氰钴胺治疗对RAU患者可能也有益。我们建议,为保护黏膜,RAU患者应达到更高的血清钴胺素水平。